- Home
- MNOV vs SRZN Comparison
MNOV vs SRZN Comparison
Compare MNOV & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- SRZN
- Stock Information
- Founded
- MNOV 2000
- SRZN 2015
- Country
- MNOV United States
- SRZN United States
- Employees
- MNOV N/A
- SRZN N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- MNOV Health Care
- SRZN Health Care
- Exchange
- MNOV Nasdaq
- SRZN Nasdaq
- Market Cap
- MNOV 73.1M
- SRZN 82.8M
- IPO Year
- MNOV 2005
- SRZN N/A
- Fundamental
- Price
- MNOV $1.41
- SRZN $7.96
- Analyst Decision
- MNOV Strong Buy
- SRZN Strong Buy
- Analyst Count
- MNOV 1
- SRZN 2
- Target Price
- MNOV $9.00
- SRZN $38.50
- AVG Volume (30 Days)
- MNOV 11.3K
- SRZN 12.8K
- Earning Date
- MNOV 05-13-2025
- SRZN 05-09-2025
- Dividend Yield
- MNOV N/A
- SRZN N/A
- EPS Growth
- MNOV N/A
- SRZN N/A
- EPS
- MNOV N/A
- SRZN N/A
- Revenue
- MNOV N/A
- SRZN $11,638,000.00
- Revenue This Year
- MNOV N/A
- SRZN N/A
- Revenue Next Year
- MNOV N/A
- SRZN N/A
- P/E Ratio
- MNOV N/A
- SRZN N/A
- Revenue Growth
- MNOV N/A
- SRZN N/A
- 52 Week Low
- MNOV $1.12
- SRZN $5.90
- 52 Week High
- MNOV $2.55
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- MNOV 47.13
- SRZN 43.91
- Support Level
- MNOV $1.34
- SRZN $5.90
- Resistance Level
- MNOV $1.45
- SRZN $8.14
- Average True Range (ATR)
- MNOV 0.07
- SRZN 0.97
- MACD
- MNOV -0.01
- SRZN 0.03
- Stochastic Oscillator
- MNOV 52.17
- SRZN 48.24
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).